IVF with Endometriosis: Success Rates by Stage, Endometrioma Management & Protocol Optimisation
Endometriosis is the leading gynaecological cause of infertility, yet IVF outcomes vary enormously depending on disease stage, ovarian reserve, and treatment protocol. Here is the evidence-based picture — and what can be done to optimise each factor.
Quick answer: IVF live birth rates with endometriosis are approximately 35–45% per transfer for Stage I–II, 30–38% for Stage III, and 20–30% for Stage IV. The long GnRH agonist downregulation protocol (3–6 months pre-stimulation) improves Stage III–IV outcomes by 15–20% over standard antagonist protocols. ESHRE guidelines advise against routine endometrioma surgery before IVF for cysts under 4 cm, as surgery permanently reduces AMH. Antioxidant priming (CoQ10, melatonin, DHEA) for 3 months before stimulation can partially offset oxidative damage to oocytes.
IVF Success Rates by Endometriosis Stage
The ASRM classifies endometriosis in four stages based on lesion depth, location, and adhesion extent (Stage I minimal → Stage IV severe). IVF outcomes track this staging — but the relationship is not simply linear, because Stage I–II patients may still have significantly altered peritoneal fluid that impairs oocyte quality despite limited anatomical disease.
Stage I — Minimal
35–45%Live birth rate per transfer. Superficial lesions only. Ovarian reserve usually preserved. IVF outcomes approach general population rates.
Stage II — Mild
35–42%Deeper implants, no endometriomas. Peritoneal inflammatory environment may reduce fertilisation rate by 5–10% vs Stage I.
Stage III — Moderate
28–38%Endometriomas present (usually unilateral). AMH may be reduced. Long protocol improves outcomes. More eggs needed per cohort.
Stage IV — Severe
20–30%Bilateral endometriomas, extensive adhesions. Lowest ovarian reserve. Multiple cycles often needed. PGT-A recommended to optimise each transfer.
Why Stage Alone Is Not the Full Story
Two patients with identical Stage III classification can have very different IVF outcomes depending on: AMH level (how much reserve remains), whether previous ovarian surgery has been performed, presence of adenomyosis, and age at time of IVF. A woman aged 30 with Stage III endometriosis and AMH 1.2 ng/mL has meaningfully different prognosis from a 39-year-old with the same stage and AMH 0.4 ng/mL. Prognosis must always be individualised.
Endometrioma Before IVF: Surgery or Direct IVF?
This is one of the most debated decisions in reproductive medicine. The concern is dual: endometrioma fluid is directly toxic to adjacent ovarian follicles, potentially impairing oocyte quality — but ovarian surgery also destroys healthy cortex and permanently reduces AMH. ESHRE's 2022 updated endometriosis guideline provides the clearest evidence-based framework.
✂️ Surgery First — When Recommended
- Endometrioma ≥4 cm limiting follicle access during egg collection
- Rapid growth of cyst between scans
- Diagnostic uncertainty — cannot exclude borderline/malignant ovarian cyst
- Pain symptoms severe enough to impair daily function
- Unilateral cyst on an ovary with good AFC on the other side (reserve can be preserved)
🔬 Direct IVF — ESHRE Preferred for Most
- Stable endometrioma <4 cm with good transvaginal access to follicles
- Already reduced AMH — surgery would worsen reserve further
- Bilateral endometriomas — bilateral surgery carries high risk of surgical menopause
- Previous ipsilateral ovarian surgery — repeat surgery causes greater cortex loss
- Patient in her late 30s — time is a factor; delay for surgery reduces IVF success with age
The AMH Cost of Endometrioma Surgery
Multiple studies quantify the AMH reduction after laparoscopic endometrioma cystectomy:
- Unilateral cystectomy: AMH declines by approximately 30–40% — often permanent
- Bilateral cystectomy: AMH declines by 55–70% — severe and frequently irreversible
- Second surgery on same ovary: high risk of complete loss of that ovary's reserve
For patients already in the low-AMH range (<1.0 ng/mL), surgery can push them to a point where IVF stimulation is no longer viable. Direct IVF, with careful ultrasound-guided aspiration of the endometrioma fluid during egg collection if needed, is the preferred path to preserve whatever reserve remains.
Optimising IVF Protocol for Endometriosis
| Protocol | Description | Best for | Evidence |
|---|---|---|---|
| Long GnRH agonist downregulation | GnRH agonist (triptorelin/leuprolide) for 3–6 months before stimulation to suppress disease and improve endometrial receptivity | Stage III–IV; recurrent implantation failure with endometriosis | Meta-analyses: 15–20% higher clinical pregnancy rate vs antagonist in moderate–severe endo |
| Short GnRH antagonist | Standard protocol; antagonist added mid-stimulation to prevent premature LH surge | Stage I–II; low AMH patients where stimulation efficiency matters | Comparable to long protocol in mild endometriosis; shorter and lower cost |
| Freeze-all (FET) strategy | All embryos frozen at blastocyst; no fresh transfer; transfer in separate cycle | All endometriosis patients — avoids fresh transfer in inflamed peritoneal environment | Several RCTs show higher live birth rates with FET vs fresh in endometriosis (ESHRE 2022) |
| PGT-A | Genetic biopsy of blastocysts to select euploid embryos | Stage III–IV, age ≥35, prior failed transfers, reduced AMH | Maximises implantation probability per transfer when egg numbers are limited |
Antioxidant Priming to Improve Oocyte Quality
Endometriosis creates elevated reactive oxygen species (ROS) in peritoneal fluid and follicular fluid, directly damaging oocyte mitochondrial function. A 3-month antioxidant pre-treatment course before IVF stimulation can partially counteract this oxidative insult:
Improves mitochondrial energy production in oocytes
High antioxidant activity in follicular fluid; reduces ROS
Supports ovarian reserve; evidence strongest in low AMH patients
Systemic antioxidant protection
Reduces systemic inflammation; improves embryo development
These supplements are typically started 90 days (3 months) before the planned egg collection cycle, as the human oocyte maturation cycle takes approximately 90 days (folliculogenesis). Supplements should be discussed with your doctor — DHEA in particular is contraindicated in PCOS patients due to its androgenic effect.
Why Freeze-All (FET) Is Usually Better Than Fresh Transfer in Endometriosis
During a fresh IVF cycle, the peritoneal fluid inflammatory environment — already elevated by endometriosis — is further amplified by the hyperstimulation of egg collection. Multiple studies now confirm that transferring embryos in a separate, unstimulated frozen embryo transfer (FET) cycle, when the endometrium is calm, produces higher implantation and live birth rates in endometriosis patients than a fresh transfer in the same stimulation cycle.
The freeze-all strategy also allows time for the ERA test to confirm personalised transfer timing — combining two improvements in a single strategy for high-risk RIF patients with endometriosis.
For an in-depth look at diagnosing endometriosis and understanding the ASRM staging system, see Endometriosis Symptoms & Diagnosis. For patients who have experienced IVF failure specifically, the broader investigation guide covers all causes: Why IVF Fails With Good Embryos.
At Mother Hospitals gynaecology unit, our reproductive medicine team holds a joint endometriosis–fertility clinic, so your disease management and IVF planning are optimised in the same consultation rather than in siloed specialties.